These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30377816)

  • 1. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Vitamin D and Dexamethasone on Lymphocyte Proportions and Their Associations With Serum Concentrations of 25-Hydroxyvitamin D
    Cho EB; Shin JH; Kwon S; Kim J; Seok JM; Kim BJ; Min JH
    Front Immunol; 2021; 12():677041. PubMed ID: 34394078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
    Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
    Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
    Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
    Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
    Cho EB; Cho HJ; Seok JM; Min JH; Kang ES; Kim BJ
    Neurol Sci; 2018 Mar; 39(3):543-549. PubMed ID: 29349658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
    de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
    Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.
    AbdelRazek MA; Casasola M; Mollashahi R; Brodski A; Morin S; Augustynowicz A; Jassim S; Matiello M; Sloane J
    Mult Scler Relat Disord; 2022 Mar; 59():103505. PubMed ID: 35121247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Sechi E; Zarbo R; Biancu MA; Chessa P; Idda ML; Orrù V; Lai S; Leoni S; Solla P
    J Neuroimmunol; 2021 Sep; 358():577666. PubMed ID: 34298341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder.
    Lu T; Shu Y; Dai Y; Liu X; Chang Y; Huang Q; Kermode AG; Qiu W
    Mult Scler Relat Disord; 2018 May; 22():83-85. PubMed ID: 29621743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neutrophil-to-Lymphocyte Ratio and the Monocyte-to-Lymphocyte Ratio Predict Expanded Disability Status Scale Score at One Year in Pediatric Neuromyelitis Optica Spectrum Disorder but not in Multiple Sclerosis.
    Devlin L; Gombolay G
    Pediatr Neurol; 2023 Jun; 143():84-88. PubMed ID: 37044044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
    Nosadini M; Alper G; Riney CJ; Benson LA; Mohammad SS; Ramanathan S; Nolan M; Appleton R; Leventer RJ; Deiva K; Brilot F; Gorman MP; Waldman AT; Banwell B; Dale RC
    Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e188. PubMed ID: 26819962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.